echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novartis DP2 receptor antagonist fevipiprant two Phase III clinical studies fail

    Novartis DP2 receptor antagonist fevipiprant two Phase III clinical studies fail

    • Last Update: 2020-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Fevipiprant is a research- novel, steroid-free daily drug that blocks the DP2 pathway, a potentially important regulatory factor for the cascade of asthmaNovartis said the overall results from the two studies did not support further clinical development of fevipiprant in asthma treatmentIn these studies, fevipiprant was generally well tolerated, and adverse reactions caused by treatment were generally balanced across groups, comparable to placebosNovartis is currently analyzing detailed efficacy and safety data for the LUSTER-1 and LUSTER-2 studies and will present them to the upcoming Medical AssemblyJohn Tsai,Novartis Global Drug Development Director and Chief Medical Officer, said: "While the results of the study assessing the treatment of asthma in fevipiprant are disappointing, they help us understand the DP2 pathway in asthmaWe are very grateful to all the patients, their families and investigators who have participated in and contributed to these studiesfevipiprant molecular structure (drugbank.ca)LUSTER-1 and LUSTER-2 are two repetitive studies that are part of the VIVI Phase III projectThe project also includes SPIRIT safety studies and supplementary repetitive ZEAL-1 and ZEAL-2 studiesIn October, Novartis released the latest results of ZEAL-1 and ZEAL-2Novartis will continue to invest in assets in the field of respiratory diseases, including listed products Xolair ® (Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)) and Ultibro® Breezhaler ®8 (COPD) and Phase III The clinical development phase of the research drugs QVM1499 (moderate severe asthma) and QMF14910 (moderate severe asthma), will continue to promote research projects including asthma, chronic obstructive pulmonary disease and other high-demand areas such as iacopulmonary fibrosis and nodule diseaseoriginal origin: Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.